Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGOSTA – Regorafenib maintenance therapy in bone sarcomas
2018-004045-16Phase 3Active
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bone cancer comparing Regorafenib maintenance with Placebo maintenance (2 arms). Primary endpoint: Relapse-Free Survival. Started Jan 2019; status: active.
02
Drugs
regorafenib
03
Conditions
bone cancer
Beyond the preview
Go deeper on 2018-004045-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004045-16.